125 related articles for article (PubMed ID: 24991717)
1. Hyperhemolysis associated with marginal zone lymphoma.
Yan M; Callum J; Lin Y
Leuk Lymphoma; 2015 Mar; 56(3):829-31. PubMed ID: 24991717
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma.
Cencini E; Fabbri A; Schiattone L; Bocchia M
Leuk Lymphoma; 2019 Mar; 60(3):833-835. PubMed ID: 30234387
[No Abstract] [Full Text] [Related]
3. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.
Carter SJ; Bernstein SH; Friedberg JW; Barr PM
Leuk Res; 2011 Nov; 35(11):e223-4. PubMed ID: 21824654
[No Abstract] [Full Text] [Related]
4. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
5. Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS).
Demaria L; Henry J; Seror R; Frenzel L; Hermine O; Mariette X; Nocturne G
Br J Haematol; 2019 Feb; 184(3):472-475. PubMed ID: 29424433
[No Abstract] [Full Text] [Related]
6. Endobronchial mucosa-associated lymphoid tissue (MALT) lymphoma.
Yamasaki M; Funaishi K; Muta T; Matsumoto N; Taniwaki M; Hattori N
QJM; 2019 Oct; 112(10):807-808. PubMed ID: 30895318
[No Abstract] [Full Text] [Related]
7. Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.
Scapinello G; Pizzi M; Vio S; Nabergoj M; Visentin A; Martines A; Bonaldi L; Trentin L; Semenzato G; Piazza F
Ann Hematol; 2018 Oct; 97(10):2001-2003. PubMed ID: 29728736
[No Abstract] [Full Text] [Related]
8. IgGκ light and heavy chain amyloidosis secondary to a B-cell lymphoproliferative disorder, whole picture on a renal biopsy.
Ville S; Kandel C; Delaunay J; Cantarovich D
Nephrology (Carlton); 2020 May; 25(5):429-430. PubMed ID: 31726478
[No Abstract] [Full Text] [Related]
9. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience.
Logothetis CN; Horvat NP; Kurian T; Bello C; Chavez J; Isenalumhe L; Shah B; Sokol L; Saeed H; Pinilla J; Gaballa S
Oncol Res; 2024; 32(6):1031-1036. PubMed ID: 38827319
[TBL] [Abstract][Full Text] [Related]
11. Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
Liu Z; Markham M; Mandernach MW
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30872333
[TBL] [Abstract][Full Text] [Related]
12. Minimal change disease: an unusual presentation of marginal zone MALT lymphoma.
Inayat F; Law JK; Myers-Gurevitch PM; Seshan SV; Perlman AS
Clin Nephrol; 2016 Mar; 85(3):184-8. PubMed ID: 26636329
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience.
Laurenti L; Autore F; Innocenti I; D'Arena G; Coscia M; Mondello P; Chiusolo P; Bellesi S; Efremov DG; Sica S; Mauro FR
Leuk Lymphoma; 2016 Oct; 57(10):2429-31. PubMed ID: 26818825
[No Abstract] [Full Text] [Related]
14. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
Laribi K; Tempescul A; Ghnaya H; Denizon N; Besançon A; Anghel A; Farhi J; Truong C; Lemaire P; Poulain S; Bolle D; Ianotto JC; Baugier de Materre A
Hematol Oncol; 2017 Dec; 35(4):536-541. PubMed ID: 27443419
[TBL] [Abstract][Full Text] [Related]
15. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
[No Abstract] [Full Text] [Related]
16. Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma.
Yutaka T; Ito S; Ohigashi H; Naohiro M; Shimono J; Souichi S; Teshima T
Leuk Lymphoma; 2015; 56(11):3216-8. PubMed ID: 25760636
[No Abstract] [Full Text] [Related]
17. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
Zaja F; Ferrero S; Stelitano C; Ferrari A; Salvi F; Arcari A; Musuraca G; Botto B; Spina M; Cellini C; Patti C; Liberati AM; Minotto C; Pileri SA; Ceccarelli M; Volpetti S; Ferranti A; Drandi D; Montechiarello E; Ladetto M; Carmichael J; Fanin R
Haematologica; 2017 May; 102(5):e203-e206. PubMed ID: 28082342
[No Abstract] [Full Text] [Related]
18. CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.
Hsu A; Kurt H; Zayac AS; Olszewski AJ
Leuk Lymphoma; 2022 Jan; 63(1):31-42. PubMed ID: 34467833
[TBL] [Abstract][Full Text] [Related]
19. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
Hitz F; Zucca E; Pabst T; Fischer N; Cairoli A; Samaras P; Caspar CB; Mach N; Krasniqi F; Schmidt A; Rothermundt C; Enoiu M; Eckhardt K; Berardi Vilei S; Rondeau S; Mey U
Br J Haematol; 2016 Jul; 174(2):255-63. PubMed ID: 27018242
[TBL] [Abstract][Full Text] [Related]
20. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab.
Kalpadakis C; Pangalis GA; Sachanas S; Rontogianni D; Korkolopoulou P; Milionis V; Vassilakopoulos TP; Papadaki HA; Angelopoulou MK
Leuk Lymphoma; 2016 Nov; 57(11):2705-8. PubMed ID: 27082039
[No Abstract] [Full Text] [Related]
[Next] [New Search]
